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In vitro lymphocyte blastogenic responses to the commonly employed mitogens
phytohemagglutinin, pokeweed, and concanavalin A were evaluated when acyclo-
vir, adenine arabinoside, cytosine arabinoside, and idoxuridine were added to the
culture materials. Similarly, specific antigen-induced blastogenic responses, in-
cluding herpes group antigens, and cytotoxicity and leukocyte inhibitory factor
assays with herpes group viruses were determined in the presence and absence of
antiviral agents. No depression of these cellular immune responses by acyclovir
or adenine arabinoside was demonstrated. This was in contrast to the effects of
cytosine arabinoside and idoxuridine, which severely inhibited blastogenic and
cytotoxic responses but not leukocyte inhibitory factor production. Even at
concentrations up to 20 tsg/ml, the antiviral agent acyclovir did not depress
selected cellular immune responses that are important for successful elimination
of invading herpes group viruses.
The efficacy of antiviral chemotherapeutic
agents is determined primarily by their ability
to inhibit viral replication. However, it has be-
come apparent in the clinical setting that suc-
cessful eradication of certain viral infections re-
quires some degree of host immune competence,
especially when infection is severe (15). There-
fore, it seems important that, while inhibiting
viral replication, antiviral chemotherapeutic
agents must not suppress host immunity below
as-yet-undefined limits.
Defense against viral infection involves a com-
plex interplay between humoral and cell-me-
diated immune responses, and although the rel-
ative contributions of the two have not been
fully delineated, the severe or fatal infections in
children with thymic deficiency syndromes or in
patients on immunosuppressive therapy suggest
that cellular immunity is certainly one of the
major host factors in combating herpes group
viral disease (16). Therefore, antiviral chemo-
therapy agents that unduly depress the host's
cellular immune responses without complete
eradication of the virus could result in relapse of
disease upon withdrawal of therapy. Previous
laboratory and clinical reports have suggested
that those antiviral agents that produce signifi-
cant immunosuppression (13) prove to be quite
limited therapeutically and are potentially more
dangerous than the disease itself (19).
A new antiviral agent, 9-(2-hydroxyethoxy-
methyl)guanine (acyclovir), has been investi-
gated for its activity against herpesviruses in
vitro and in infected animal models (1, 5-12) and
is currently being introduced into human clinical
studies. Acyclovir has been demonstrated to
have low toxicity for normal cells in vitro (4) and
strong antiviral activity against members of the
herpes group of viruses, with a safety index
(concentrations associated with toxicity divided
by therapeutic concentrations) in tissue culture
of approximately 3,000 (11). In vivo efficacy of
acyclovir has been demonstrated in several ani-
mal models when administered parenterally,
orally, and as cutaneous and ophthalmic oint-
ments (1, 5-12).
The studies discussed in this report were de-
signed to seek possible immunotoxic effects of
acyclovir on mechanisms of cellular immunity in
comparison to other antiviral agents.
MATERLU1S AND METHODS
Immunological assays. The following in vitro
correlates of immune function were examined: (i) mi-
togen-induced blastogenesis; (ii) antigen-induced blas-
togenesis; (iii) direct lymphocyte cytotoxicity to MA-
160 cells persistently infected with herpes group vi-
ruses; (iv) leukocyte inhibitory factor (LIF) production
in response to herpes group viruses.
Isolation of lymphocytes. Lymphocytes were
separated from peripheral whole blood by centrifuga-
tion on a Hypaque-Ficoll gradient as previously de-
scribed (21). These lymphocytes were obtained from
donors who were immune, and some who were not
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experimental day to provide appropriate negative and
positive controls.
Mitogen stimulation. Using a biopipette, 0.1 ml of
the lymphocyte suspension (2 x 105 lymphocytes) was
added to an equal volume of various concentrations of
the mitogens phytohemagglutinin, pokeweed, and con-
canavalin A, with each in one well of sterile flat-
bottom microtest plates. A harvesting apparatus, pre-
viously described and technically refined for our use,
was employed for separation of the stimulated lym-
phocytes on glass-fiber filters, for washing of these
cells, and for recovery of radioactive [3H]thymidine
uptake (14). The average counts per minute of tripli-
cate samples were determined, and results were ex-
pressed as a blastogenic index (BI): counts per minute
of [3H]thymidine uptake for lymphocytes incubated
with mitogen, divided by uptake after incubation with
medium alone.
Cell cultures persistently infected with herpes
group viruses. Cell line MA-160, derived from hu-
man prostate adenoma tissue, was inoculated with
herpes simplex type 1 (HSV-1), HSV-2, varicella-zos-
ter virus, or cytomegalovirus at a multiplicity of infec-
tion of 1. The development of the resulting infected
cell lines is described in a separate communication
(18). Both the control MA-160 and virus-infected cell
lines were monitored before use for surface membrane
antigen by indirect immunofluorescence. An average
of 60 to 70% of the infected cells fluoresced. Control
cells did not fluoresce.
Assays of antigen-induced lymphocyte blas-
togenesis. Blastogenic responses to Candida albi-
cans (Dermatophytin "O", Hollister-Stier Laborato-
ries, Inc., Yeadon, Pa.) and tetanus toxoid (Merrell-
National Laboratories, Cincinnati, Ohio) were deter-
mined as previously described (17). Methods for
herpes group virus-induced blastogenesis with infected
MA-160 cells were similar to those employed for a
one-way mixed lymphocyte culture (20). Simultaneous
controls were run using uninfected MA-160 cells.
Counts per minute for lymphocytes incubated with
uninfected MA-160 cells showed very little variation
throughout the study, averaging approximately 1,200.
Therefore, observed changes in BIs could not be ac-
counted for by changes in control cultures.
Assays of lymphocyte cytotoxicity. A 5"Cr mi-
croassay of lymphocytotoxicity to the cell lines per-
sistently infected with HSV-1, HSV-2, or varicella-
zoster virus was used in these studies. Details of the
microassay were described previously (14). Briefly,
this technique examines lymphocyte-target cell inter-
action, employing the infected cell lines described
above as the target cells. The quantitative release of
51Cr from these target cells is used as an index of
lymphocyte-mediated cytotoxicity against the unin-
fected cells. Uninfected cells served as controls to
quantitate 5'Cr release not attributable to the virus
itself. Target cell suspensions were labeled with 51Cr
(Na5'Cr; New England Nuclear Corp.; specific activity,
50 to 500 Ci/g) by incubating 107 cells in 1 ml of
medium containing 100 jiCi of 51Cr for 45 min as
described previously.
A sample of 0.1 ml of lymphocytes (5 x 105) was
incubated with 0.1 ml of target cells (5 x 103) in flat-
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bottom microtest plates. Target cells were also com-
bined with 0.1 ml of medium alone for determination
of spontaneous release of 5'Cr. All cultures on the
microtest plate were prepared in triplicate. The plates
were covered with sterile plastic lids and placed on a
rocker platform at 37°C in an atmosphere of 5% C02.
The cell suspensions were harvested (with the appa-
ratus described above) after incubation for 24 h. The
total amount of 5"Cr available for release was deter-
mined by placing 0.1 ml of the target cell suspension
directly in a gamma counting tube; zero-time samples
were also harvested when incubation of the assay
materials was begun. To determine lymphocyte-me-
diated cytotoxicity specific for HSV-1, the amount of
5'Cr released spontaneously from infected target cells
(I) and control cells (C) was subtracted from the
amount released during the interaction oflymphocytes
with infected target cells (IL) or control cells (C"),
respectively. The amount released at zero time was
subtracted from the total amount of 5"Cr that was
available for release during the incubation period.
Finally, the specific immune release (SIR) was calcu-
lated by subtraction of the percentage of 5"Cr released
from control target cells from the percentage released
from infected cells, according to the following formula:
% SIR = [(IL-I)I(T, - zero-timei) - (CL -C)I(T
- zero-time,)] x 100.
LIF production. LIF was determined by methods
previously described (3). Briefly, 30 ml of heparinized
blood was obtained from each subject and dextran
sedimented to isolate leukocytes. Cells were reconsti-
tuted with 10% horse serum to a concentration of 108
per ml. Antigens in this assay were herpes group-
infected MA-160 cells; a control antigen preparation
was uninfected MA-160 cells. The ratio of infected
MA-160 cells to leukocytes for these assays was 1:3. A
total of 106 cells were placed into a test tube, and 50
pl of leukocyte suspension was added at 37°C for 30
min in 5% CO2. An agarose medium containing 1%
agarose, single-strength tissue culture medium 199,
10% horse serum, 66 IU of penicillin per ml, and 66 ,ug
of streptomycin per ml was transferred to disposable
plastic petri dishes (48 by 8.5 mm; Millipore Corp.).
Six wells were punched in the gel with a 2.5-mm
(external diameter) gel puncher. Agarose plates with
the leukocyte antigen mixtures were then incubated
at 37°C in a 5% C02-air mixture for 16 to 20 h. At the
end of this time, the area of migration of leukocytes
was measured, and the percent migration was calcu-
lated by dividing the area of migration with antigen
by the area of the migration in the control wells, as
follows: Percent inhibition = 1.0 - (area of migration
for leukocytes with antigen/area of migration for leu-
kocytes without antigen) x 100%.
Antiviral agents. The following antiviral agents
were evaluated: (i) acyclovir (Burroughs Wellcome
Co., Research Triangle Park, N.C.); (ii) adenine ara-
binoside (ara-A; Parke, Davis and Co., Ann Arbor,
Mich.); (iii) cytosine arabinoside (ara-C; The Upjohn
Co., Kalamazoo, Mich.); and (iv) idoxuridine (IDU;
Calbiochem, San Diego, Calif.). Concentrations of the
antiviral agents known to suppress herpes group vi-
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effective dose of acyclovir is as low as 0.02 ,ug/ml
against HSV-1, various concentrations up to 20 Ag/ml
are presented, since no cytotoxicity was observed up
to this level.
RESULTS
Mitogen blastogenesis. The effects of the
four antiviral agents on mitogen-induced blas-
togenesis are presented in Fig. 1 to 3. Experi-
ments were repeated five times with lympho-
cytes from each of 10 adult donors, and results
were averaged for these three figures. Ara-C and
IDU significantly depressed lymphocyte blasto-
genic responses to phytohemagglutinin, poke-
weed mitogen, and concanavalin A, whereas acy-
clovir and ara-A demonstrated no significant
toxic effects.
These assays were also conducted with varia-
ble incubation times ranging from 1 to 7 days,








72-h incubation and 5-h [3H]thymidine pulse.
Inhibition of blastogenic reactivity was not ob-
served until acyclovir concentrations of 50 ,tg/
ml were added, with marked depression noted
at 200 Ag/ml (Table 1).
Antigen-induced blastogenesis. Table 2
summarizes lymphocyte responses to a fungal
and bacterial antigen as well as reactivity spe-
cific to herpes group viruses in the presence of
antiviral agents. Ara-C severely depressed blas-
togenesis with all antigens, IDU had an inter-
mediate effect, and acyclovir and ara-A showed
no depressant effects on the assays. Results were
similar for HSV-1, HSV-2, varicella-zoster virus,
and cytomegalovirus.
Lymphocyte cytotoxicity. Cytotoxic re-
sponses of HSV-1-, HSV-2-, varicella-zoster vi-
rus-, and cytomegalovirus-infected MA-160 cells
to normal donor lymphocytes were lower when
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FIG. 1. In vitro lymphocyte blastogenesis after incubation with phytohemagglutinin, expressed as BI:
counts per minute of [3H]thymidine uptake for lymphocytes incubated with phytohemagglutinin, divided by
uptake after incubation with medium alone. ( ) control; (---) acyclovir, 20 pig/ml; (***) ara-A, 3 pg/
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FIG. 2. In vitro lymphocyte blastogenesis after incubation with pokeweed mitogen expressed as BI: counts
per minute of [3Hlthymidine uptake for lymphocytes incubated with pokeweed mitogen, divided by uptake
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FIG. 3. In vitro lymphocyte blastogenesis after incubation with concanavalin A expressed as BI: countsper
minute of [3H]thymidine uptake for lymphocytes incubated with concanavalin A, divided by uptake after
incubation with medium alone. Symbols as in Fig. 1.
TABLE 1. Mitogen-induced blastogenesis in the
presence of varying concentrations of acyclovir
% of control BHP
Acyclovir concn (jig!
ml) PHA (5 Con A (10 PWM (1jig/ml) jg/ml) jig/ml)
200 39 27 49
100 66 39 70
50 93 74 89
20 100 100 100
16 100 100 100
12 100 100 100
10 100 100 100
8 100 100 100
4 100 100 100
2 100 100 100
0.4 100 100 100
Control BIb 46 31 30
a Each figure represents the average of five separate
experiments, with each experiment done in triplicate.
PHA, Phytohemagglutinin; Con A, concanavalin A;
PWM, pokeweed mitogen.
b Counts per minute of [3H]thymidine uptake for
lymphocytes incubated with mitogen, divided by up-
take after incubation with medium alone.
ara-C or IDU was included in the tissue culture
medium (Table 3). In contrast to these agents,
neither acyclovir nor ara-A suppressed release
of 5"Cr or, presumably, cytotoxicity. However,
changes with ara-C and IDU might be in part
attributable to toxic effects on the cell lines
themselves with resulting increased nonspecific
release of 51Cr seen in uninfected control cul-
tures. This increased background tends to mag-
nify what might be small differences.
LIF production. As seen in Table 4, activity
of LIF was not significantly altered by any of the
antiviral agents studied.
DISCUSSION
Advances in the control of viral disease have
so far resulted primarily from the development
of safe and effective vaccines. However, infec-
tions following reactivation of latent viruses,
such as with members of the herpes group, are
not currently amenable to control with active
immunization, nor are they completely respon-
sive to therapy with immune globulin or specific
antibody-containing plasma. Therefore, at-
tempted therapy of herpesvirus infections has,
once again, focused on a chemotherapeutic ap-
proach. The greatest limiting factor for the use
of these agents has been toxicity resulting from
nonspecificity of anti-deoxyribonucleic acid ac-
tivity. Such toxicity has resulted in the elimi-
nation of ara-C (19) and IDU (2) from the sys-
temic antiviral chemotherapeutic armamentar-
ium. Although parenterally administered ara-A
has been successful against a limited group of
herpesvirus infections with relatively low toxic-
ity (4, 13), safer and more effective compounds
are needed. Bioactivation of acyclovir by virus-
specified thymidine kinase offers a potential
nontoxic candidate for human use (4).
Examination of the immune system is not
routinely included in preclinical toxicity testing
of investigational drugs because there is a rela-
tive lack of standardized guidelines for preclini-
cal screening of antiviral compounds at this time.
There is also an incomplete understanding of
the contribution ofimmune mechanisms in com-
bating these diseases. It is generally accepted
that recovery from viral disease is directly pro-
portionate to the degree of activity of host im-
mune mechanisms (15). It is therefore important
that antiviral chemotherapeutic agents not ren-
der the host's immunological responses less ef-
fective. This was first appreciated clinically with
the therapeutic failures of ara-C (19) and IDU
(2), attributed to bone marrow suppression and
impaired granulocyte function, but perhaps also
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TABLE 2. Specific antigen-induced blastogenesis in the presence of antiviral agents
% of control BI
Antigen Control BIG Acyclovir (20 Ara-A (3 ug/ Ara-C (10 IDU (1.5 fig/
,Ag/ml) ml) tg/ml) ml)
C. albicans 16.3 100 95 17 61
Tetanus toxoid 13.7 100 88 5 57
Herpes group viruses
HSV-1 11.4 100 100 0 41
HSV-2 17.7 100 100 0 33
Varicella-zoster virus 8.5 98 100 21 56
Cytomegalovirus 6.8 100 91 4 40
Expressed as counts of [3H]thymidine uptake per minute for lymphocytes incubated with antigen, divided
by uptake after incubation in medium alone.
TABLE 3. Lymphocyte cytotoxicity to herpes group-infected target cells in the presence of antiviral agents
% of control SIR
Cells infected with: Control SIRa Acyclovir (20 Ara-A (3 ,Lg/ Ara-C (10 jig/ IDU (1.5 Jug/
Jug/ml) il) Mi) Mi)
HSV-1 24.5 100 81 27 64
HSV-2 13.1 100 100 19 71
Varicella-zoster virus 9.9 100 100 52 39
Cytomegalovirus 17.4 100 95 53 20
a Expressed as percent specific immune release (SIR) of 51Cr attributable to intracellular virus.
TABLE 4. Herpes group virus-induced LIFproduction in the presence of antiviral agents
% of control MI
Cells infected with: Control MI'C nw(%O) Acyclovir (20 Ara-A (3 ,ug/ Ara-C (10 ,g/ IDU (1.5 tig/
Iyg/ml) ml) ml) ml)
HSV-1 31 100 100 95 100
HSV-2 19 100 100 100 95
Varicella-zoster virus 26 100 100 96 100
Cytomegalovirus 22 100 100 88 96
a MI, Migration inhibition. MI = 1 - (migration of cells with viral antigen/migration of cells without viral
antigen) x 100%.
The development of simpler assays of cellular
immune function now allows direct measure-
ment ofimmunotoxicity of antiviral agents. Such
studies were previously employed to evaluate
ara-A and demonstrated that it did not impair
host defense mechanisms in vitro (13) nor in
vivo (15). The present study has focused on
acyclovir, a recently introduced investigational
compound, and has expanded the in vitro eval-
uation of ara-A, ara-C, and IDU. Studies in mice
(G. R. Elion, unpublished data) have shown that
acyclovir at doses of 100 mg/kg per day does not
suppress delayed hypersensitivity, graft-versus-
host reaction, complement-dependent cellular
cytotoxicity, complement-independent cellular
cytotoxicity, or circulating antibody formation
to sheep erythrocytes.
Significant toxicity for ara-C and IDU was
demonstrated in assays of mitogen- and antigen-
induced blastogenesis and lymphocyte-mediated
cytotoxicity. However, production of the lym-
phokine, LIF, was not depressed. This is not
surprising, since LIF production requires protein
synthesis which should not be inhibited by
agents whose major effect is on deoxyribonucleic
acid replication. Lymphocyte cytotoxic re-
sponses were also suppressed to about half of
control values. Since these responses are not
dependent on deoxyribonucleic acid synthesis,
such effects are not as readily explained. How-
ever, it was apparent that ara-C and IDU had
direct toxic effects on the virus-infected cell
lines, thus making it more difficult to delineate
51Cr release attributable to specific lymphocyte
responses.
In contrast to ara-C and IDU, neither acyclo-
vir nor ara-A impaired selected cell-mediated
responses at concentrations of 20,ug/ml and 3
,u.g/ml, respectively. Since acyclovir actually in-
hibits some herpes group viruses at concentra-
tions as low as 0.02 ,ug/ml (4), at 20 ,ug/ml a very
high potential therapeutic index is suggested.
Inhibition of blastogenic reactivity was not ob-












962 STEELE, MARMER, AND KEENEY
ml were added, with marked depression noted
at 200 ,ug/ml. Even at 200 ,ug/ml there was no
evidence of cytotoxicity or influence on LIF as-
says.
In summary, acyclovir appears at least equally
as non-immunotoxic as ara-A with respect to
many cellular immune mechanisms. These may
be important preliminary data for consideration
during clinical evaluation of human toxicity and
efficacy. As with all new antiviral agents, thera-
peutic potential for acyclovir must be deter-
mined in appropriately designed double-blind
clinical trials.
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